Information de reference pour ce titreAccession Number: | 00129761-200601001-00004.
|
Author: | Ratner, Robert E. MD, FACE *; for the Diabetes Prevention Program Research Group +
|
Title: | AN UPDATE ON THE DIABETES PREVENTION PROGRAM.[Report]
|
Source: | Endocrine Practice. 12 (Supplement 1):20-24, January/February 2006.
|
Abstract: | Objective: To summarize the results of the Diabetes Prevention Program (DPP) and describe the additional 5-year follow-up study.
Methods: The design, implementation, and outcome of the DPP are reviewed, and an economic analysis of the effects of diabetes prevention and delay is presented.
Results: The DPP, thus far the largest diabetes prevention trial with the most ethnically diverse patient population, originally consisted of more than 3,800 subjects with impaired glucose tolerance. These subjects were randomized to receive one of four interventions: intensive lifestyle adjustments or standard lifestyle plus one of the following-placebo, metformin, or troglitazone. In June 1998, the troglitazone treatment was discontinued after a fatal case of liver failure in a study participant, but the subjects in this arm of the study continued to undergo followup. Thus, 3,234 subjects remained in the other three arms of the study. After a mean of 2.8 years of follow-up, the DPP was prematurely terminated because of an observed significant benefit to the intervention groups. Both metformin therapy and intensive lifestyle intervention reduced the risk of developing diabetes (by 31% and 58%, respectively, in comparison with placebo), and both interventions were deemed to be cost-effective on the basis of computer projections over a lifetime. Because of the premature discontinuation of the DPP, the durability of the interventions on diabetes prevention and the effect on microvascular and macrovascular disease could not be assessed. The subsequent outcomes study will address these issues during a 5-year follow-up period.
Conclusion: The DPP showed that both metformin and intensive lifestyle modifications effectively delayed or prevented the development of diabetes in a cost-effective manner.
(C) 2006 Allen Press
|
References: | 1. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes [erratum in Diabetes Care. 1999;22:1389]. Diabetes Care. 1999;22: 623-634.
2. Diabetes Prevention Program Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care. 2000;23:1619-1629.
3. Knowler WC, Barrett-Connor E, Fowler SE, et al (Diabetes Prevention Program Research Group). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
4. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25:2165-2171.
5. Wing RR, Hamman RF, Bray GA, et al (Diabetes Prevention Program Research Group). Achieving weight and activity goals among Diabetes Prevention Program lifestyle participants. Obes Res. 2004;12:1426-1434.
6. Knowler WC, Hamman RF, Edelstein SL, et al (Diabetes Prevention Program Research Group). Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005;54:1150-1156.
7. Ratner R, Goldberg R, Haffner S, et al (Diabetes Prevention Program Research Group). Impact of intensive lifestyle and metformin therapy on cardiovascular risk factors in the Diabetes Prevention Program. Diabetes Care. 2005;28:888-894.
8. Teutsch S. The cost of preventing diabetes: what do we know and what do we need to know? Diabetes Care. 2003; 26:238-239.
9. Diabetes Prevention Program Research Group. Withintrial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
10. Herman WH, Hoerger TJ, Brandle M, et al (Diabetes Prevention Program Research Group). The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323-332.
|
Language: | English.
|
Document Type: | ACE/AACE Diabetes Recommendations Implementation Conference.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 1530-891X
|
NLM Journal Code: | 9607439, dy1
|
Annotation(s) | |